Zytiga

J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer

J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer

Forbes

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Motley Fool

Can Zytiga Build on a Historic 2012?

Can Zytiga Build on a Historic 2012?

Motley Fool

J&J's Prostate Cancer Drug Zytiga Approved for Earlier Use in EU

J&J's Prostate Cancer Drug Zytiga Approved for Earlier Use in EU

Motley Fool

RNA Technology Could Save Lives, Create Investment Opportunity

RNA Technology Could Save Lives, Create Investment Opportunity

Motley Fool

Big News for This Blockbuster Drug

Big News for This Blockbuster Drug

Motley Fool

Dendreon Dodges A Bullet

Dendreon Dodges A Bullet

Seeking Alpha

FDA approves J&J's Zytiga for men who have not yet received chemotherapy for prostate tumors

FDA approves J&J's Zytiga for men who have not yet received chemotherapy for prostate tumors

Yahoo/AP

Zytiga, Xtandi will help pump prostate cancer market to $9.1B

Zytiga, Xtandi will help pump prostate cancer market to $9.1B

Fierce Pharma

J&J's Zytiga to be reviewed faster by FDA for additional use

J&J's Zytiga to be reviewed faster by FDA for additional use

Reuters